Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.08.2023 | Case report

Dacomitinib

Purpuric drug eruptions: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Chang HC, et al. Dacomitinib-induced purpuric drug eruptions associated with IQGAP1 upregulation in a patient with lung adenocarcinoma. Journal der Deutschen Dermatologischen Gesellschaft 21: 795-797, No. 7, Jul 2023. Available from: URL: http://doi.org/10.1111/ddg.15067 Chang HC, et al. Dacomitinib-induced purpuric drug eruptions associated with IQGAP1 upregulation in a patient with lung adenocarcinoma. Journal der Deutschen Dermatologischen Gesellschaft 21: 795-797, No. 7, Jul 2023. Available from: URL: http://​doi.​org/​10.​1111/​ddg.​15067
Metadaten
Titel
Dacomitinib
Purpuric drug eruptions: case report
Publikationsdatum
01.08.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-45219-2

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Thiamazole

Case report

Multiple drugs

Case report

Sunitinib

Case report

Azd-1222

Case report

Iron-sucrose